Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, Others), By Therapeutic Area (Respiratory, Pain & Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective, CNS, Dermatology, Genitourinary), By Drug Type (Small Molecules, Large Molecules/Biopharmaceuticals), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Drug Discovery Outsourcing Market Size

The global drug discovery outsourcing market size was valued at USD 6.65 billion in 2025 and is projected to grow from USD 7.16 billion in 2026 to USD 12.86 billion by 2034, registering a CAGR of 7.6% during the forecast period from 2026 to 2034. North America dominated the drug discovery outsourcing market with a market share of 42.1% in 2025.

In several pharmaceuticals, pharmacology, and biotechnology areas, new drugs or medicines are discovered through the outsourcing of drug discovery. Additionally, the process of developing drugs begins with outsourcing drug discovery. One of the most significant factors propelling the global demand for the expansion of the drug discovery outsourcing market is the rise in collaboration trends in research on new drugs. In addition, the forecasted market growth would be influenced by factors such as the increased prevalence of genetic, metabolic, and other chronic disorders, technological developments, and medication discovery and research. Additionally, a rise in the use of artificial intelligence (A.I.) in drug discovery, a change in patent biologics, the expiration of patents, and an unprecedented reduction in internal pharmaceutical company research and development budgets are all predicted to boost market growth.

Workflow Insights

The global market is bifurcated into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow. Lead identification & candidate optimization dominated the market and is anticipated to register a CAGR of 7.7% during the forecast period. This step of drug development involves the Quantitative Structure-Activity Relationship (QSAR) and structure-based optimization of the generated lead compound. It also requires the optimization of drug candidates before human dose preparation. The presence of multiple tools for predicting drug safety using in silico techniques results in a larger share of the segment in drug development informatics. Massive investment by key pharma companies for drug discovery is anticipated to boost the revenue generation of this segment.

Request Customizationto receive a tailored report.

Therapeutics Area Insights

The global market is segmented into the respiratory system, pain, and anesthesia, oncology, ophthalmology, hematology, endocrine, gastrointestinal, immunomodulation, anti-infective, cardiovascular, central nervous system, dermatology, genitourinary system. The respiratory system dominated the market and is estimated to register a CAGR of 6.9% during the forecast period. An increase in the incidence of major respiratory disorders such as lung cancer, bronchitis, tuberculosis, Chronic Obstructive Pulmonary Diseases (COPD), and asthma boosts the drug discovery outsourcing market to develop new therapies to combat such diseases. According to WHO, more than 3 million people suffered from COPD in 2015, and 1.8 million died due to the disease. Globally, in 2015, an estimated 480,000 people developed Multidrug-Resistant TB (MDR-TB), which prompted companies to discover and develop potential drugs. Private players are continuously working on evolving new medicines for respiratory system disorders. For instance, in 2012, Evotech and I.R. Pharma collaborated on respiratory drug discovery. Similarly, in 2014, AstraZeneca and Charles River Laboratories developed a new respiratory drug candidate to move into preclinical development. Such initiatives for discovering novel drugs for respiratory system disorders aid revenue generation.

Drug Type Insights

The global market is segmented into small and large molecules (biopharmaceuticals). The small molecule segment dominated the market and is estimated to register a CAGR of 6.9% during the forecast period. Small molecule synthesis is a viable drug discovery and development pathway for novel and generic products. Small molecules differ from other drug compounds, such as proteins and biologics. Small molecules developed for oncology therapies penetrate the cell wall and target the cell. Small molecules are thus used in cytotoxic chemotherapy to exploit the generic vulnerabilities of a tumor. Most of the new drugs in the market are based on this capability of small molecules. Such applications drive segment growth.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America dominated the market and is estimated to register a CAGR of 6.8% during the forecast period. The U.S. is among the critical needs in the international pharmaceutical industry and is responsible for around 80% of global pharmaceutical sales. Significant factors such as developed infrastructure, increase in R&D investment, and rise in the incidence of various diseases are driving the growth of the drug discovery outsourcing market in the U.S. In addition, public-private partnerships formed to develop novel drug molecules are expected to impact the market growth in this region dramatically. Furthermore, the U.S. pharmaceutical industry has generated more novel drug substances than its European and Japanese counterparts every five years since 1965. A significant factor that makes the U.S. attractive for pharmaceutical R&D investment is that companies are relatively free in pricing their drugs. This helps them recoup their R&D investment and thus encourages further productivity.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Drug Discovery Outsourcing Market Trends

Europe is the second largest region. It is estimated to reach an expected USD 17 million by 2030 at a CAGR of 7.1%. Various research initiatives of the U.K. government in alliance with many private firms are expected to increase the potential of the U.K. drug discovery outsourcing market. The European Lead Factory, a collaborative public-private partnership launched a platform for discovering high-quality drug molecules that were previously inaccessible. Seven top-notch firms, such as AstraZeneca; Bayer Pharma; Merck KGaA; Lundbeck; UCB Pharma; Janssen Pharmaceuticals; and Sanofi, came together to give the European research community access to their guarded compound libraries. Screening centers in U.K. and Netherlands use high throughput screening techniques to screen around 50,000 vital compounds. Research councils in the U.K. invest in advancing healthcare research, which is anticipated to have a positive effect on the market expansion of this nation.

Third in size, is the Asia-Pacific region. Over the projected period, the drug discovery outsourcing market in Asia Pacific is estimated to develop at the quickest rate. Since most patients in this region pay for their medications out of pocket, the developing economies of Asian nations play a significant role in expanding this market. The Asian drug discovery outsourcing market is also expected to increase because of ongoing drug discovery research, public-private partnerships, and government initiatives.

List of Key and Emerging Players in Drug Discovery Outsourcing Market